



Clostridium difficile colonization and/or infection during infancy and the risk of childhood allergic diseases

Sun Hwa Lee, MD¹, Yun Na Gong, MD², Eell Ryoo, MD, PhD¹

¹Department of Pediatrics, Gachon University Gil Medical Center, ²Graduate School of Medicine, Gachon University, Incheon, Korea

Purpose: The gut microbiota can influence several diseases through immune modulation; however, the exact role of microbes such as *Clostridium difficile* and the relationship between microbiota colonization and allergic diseases are not well known. This study aimed to determine the relationship between *C. difficile* colonization and/or infection (CDCI) during infancy and allergic diseases during early childhood.

Methods: Infants 1–12 months of age presenting changes in bowel habits for more than 2 weeks were enrolled in this study. After dividing them into 2 groups according to the presence and absence of *C. difficile*, the risk of allergic disease development during childhood was identified and compared.

Results: Sixty-five patients were included in this study; 22 (33.8%) were diagnosed with CDCI. No significant differences were observed in baseline characteristics between the *C. difficile*-positive and -negative groups except for antibiotic exposure (22.7% vs. 60.5%, $P=0.004$). Compared to the *C. difficile*-negative group, the risk of developing at least one allergic disease was higher in the *C. difficile*-positive group after adjusting other variables (adjusted odds ratios, 5.61; 95% confidence interval, 1.52–20.74; $P=0.007$). Furthermore, food allergies were more prevalent in the *C. difficile*-positive group ($P=0.03$).

Conclusion: CDCI during infancy were associated with a higher risk of developing allergic diseases during early childhood. These results suggest that CDCI during infancy might reflect the reduced diversity of the intestinal microbiota, which is associated with an increased risk of allergic sensitization. To identify the underlying mechanism, further investigation and a larger cohort study will be needed.

Key words: Allergy, Allergic diseases, *Clostridium difficile*, Gut microbiota, Food allergy

Corresponding author: Eell Ryoo, MD, PhD
Department of Pediatrics, Gachon University Gil
Medical Center, 21 Namdong-daero 774beon-gil,
Namdong-gu, Incheon 21565, Korea
Tel: +82-32-460-3224
Fax: +82-32-460-3224
E-mail: ryoo518@gilhospital.com

Received: 9 June, 2016
Revised: 29 December, 2016
Accepted: 11 January, 2017

Introduction

The intestinal microbiota is a key source of immune development and regulation early in life. Deprivation of microbial exposure is thought to predispose to immune dysregulation and the development of atopic disease¹. In particular, alterations in microbial exposure and the gastrointestinal microbiota early in life can influence allergic sensitization²⁻⁵. Hygiene hypothesis has suggested that microbial exposure early in life plays a critical role in developing the immune system, thereby avoiding the development of allergic diseases⁶. Recent studies have demonstrated that the gastrointestinal microbiota plays a definitive role in atopy development. Colonization of neonatal germ-free mice with a conventional microbiota protected these animals from mucosal invariant natural killer T-cell accumulation⁷. In addition, B cells isolated from gut-associated lymphoid tissues can induce the development of regulator T cells and alleviate asthmatic symptoms^{8,9}. Liao et al.¹⁰ demonstrated an age-matched response to Toll-like receptor stimulations during the first 2

Copyright © 2017 by The Korean Pediatric Society

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

years of life, thus providing strong evidence for the establishment of immune modulation and maturation in neonates.

Clostridium difficile is a gram-positive, anaerobic, spore-forming rod bacterium that colonizes in 10% to 70% of children younger than 12 months of age¹¹. When the normal colonic microbiota is disrupted, *C. difficile* can propagate and cause infection¹². The overall disease spectrum can range from asymptomatic colonization to severe infection exhibited by severe diarrhea^{13,14}. Although specific harmful or protective species of microbes have not yet been identified, there is limited evidence indicating that *C. difficile* might be one of the microbes associated with atopy⁵. A recent study has reported that clusters IV and XIVa of genus *Clostridium* can induce colonic-regulatory T cells for regulating immune responses¹⁵. Although the importance of gut bacteria in allergic diseases is undeniable, how individual bacteria species affect allergic disease development is not yet well known. The increasing incidence of atopy might be due to the increasing incidence of community-acquired *C. difficile* infection in younger children¹⁶. The influence of *C. difficile* colonization and/or infection (CDCI) during infancy after the settlement of normal flora in the gastrointestinal tract on allergic diseases during late childhood remains unknown.

To determine the relationship between CDCI during infancy and the development of allergic diseases during childhood, we hypothesized that CDCI during infancy could alter gut microbiota and increase the risk of development of allergic diseases during early childhood.

Materials and methods

1. Study design and population

Infants 1 to 12 months of age who were admitted to the pediatric gastrointestinal clinic at Gachon University Gil Medical Center between June 2009 and December 2012 were enrolled in this study. These infants had either a change in bowel habits or diarrhea for more than 2 weeks as their main symptom. They underwent laboratory stool tests, including *C. difficile* testing. Demographic information such as sex, age, mode of delivery, gestational age, birth weight, admission history to a neonatal intensive care unit, duration of breastfeeding, maternal age at delivery, birth order, antibiotic exposure, and eosinophil count were obtained from the medical records and analyzed retrospectively. Antibiotic exposure was defined as positive when the child had ever been administered oral antibiotics for more than 3 consecutive days. No distinction was made between different antibiotics or multiple courses of antibiotics versus a single course. After at least 2 years, the history of allergic disease was collected via parental report questionnaires. Exclusion criteria were as follows: previously confirmed allergic disease, lactose intolerance,

documented systemic disease, immune deficiency, immunosuppressive therapy, history of receiving blood products during the prior 3 months, patients who did not undergo stool analysis, records lacking information regarding baseline characteristics, or inability to contact. Lactose intolerance was defined on the basis of a history of improvement in the symptoms of diarrhea after the ingestion of lactose-free formula. All patients were enrolled after fully informed consent was obtained from their parents. This study was approved by the Institutional Review Board of Gachon University Gil Medical Center (approval number: GBIRB2016-163).

2. Microbial analysis

Naturally passed stool samples were collected from the diaper of each infant after defecation. Diagnosis of CDCI were confirmed when *C. difficile* was identified in the stool culture and/or rapid immunoassay was positive for *C. difficile* toxins A and B. The *C. difficile*-positive group included *C. difficile* colonization and/or infection. The *C. difficile*-negative group had negative results for both tests. At the same time, rotavirus testing was performed for stool samples. Additionally, a respiratory virus test was performed if patients had respiratory symptoms. Extraction of toxin A and toxin B from *C. difficile* was conducted using an enzyme-linked fluorescent immunoassay (VIDAS CDAB, BioMerieux SA, Marcy l'Etoile, France). For the *C. difficile* stool culture, the collected stool was placed onto culture media of ChromID *C. difficile* agar (BioMerieux SA) and an anaerobic culture was conducted for 48 to 72 hours. Colonies grew black, which contrasted sharply with the clear background of the agar. This enabled easy detection of *C. difficile*. We used oral metronidazole 20 mg/kg per day for 10 days for toxin-positive cases if there was no improvement using conservative management.

3. Definition of allergic disease outcomes

After at least 2 years, the history of allergic diseases was collected through parent-reported questionnaires. In the survey, a Korean version of the International Study of Asthma and Allergies in Childhood questionnaire¹⁷ was used; the characteristics of this survey have been reported in detail elsewhere. Asthma prevalence was determined by lifetime and current (past 12 months) wheezing episodes. We also recorded whether the asthma had been diagnosed by a doctor and whether treatment had occurred in the past 12 months. Similar questions were also asked in regard to atopic dermatitis (AD), allergic rhinitis (AR), and food allergy (FA).

4. Statistical analysis

The chi-square test and Fisher exact test were used to evaluate demographic markers and estimate unadjusted odds ratios (ORs) and relative risks (RRs) with a 95% confidence interval (CI) for the outcomes of asthma, AR, AD, and FA. Logistic regression models

were used to estimate adjusted ORs (aORs) with a 95% CI for the outcomes of the *C. difficile*-negative group and potential confounding effects such as gender, age when the fecal sample was collected, gestational age, birth weight, breastfeeding, and parents with allergic diseases. All statistical analyses were performed using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA), $P < 0.05$ was considered significant.

Results

1. Characteristics of the study population

Of the 71 patients, 6 were excluded from the study due to lactose intolerance ($n=2$), history of AD ($n=2$), and loss to follow-up ($n=2$). The remaining 65 infants were divided into 2 groups according to the presence of CDCI. Twenty-two infants (33.8%) were positive for *C. difficile* and 43 (66.2%) were negative. In the *C. difficile*-negative group, one patient had rotavirus and 4 patients had a viral respiratory infection (respiratory syncytial virus subgroup B for 3; adenovirus for 1). Other pathogens were not confirmed. The mean age when fecal samples were collected was 5.5 ± 2.9 months. Of the 65 infants, 33 (50.8%) were male (Table 1). Except for antibiotic exposure, no significant differences were observed in the mode of delivery, gestational age, birth weight, maternal age at birth, birth order, duration of breastfeeding, history of neonatal intensive care unit admission, or parental history of allergic diseases between the 2 groups (22.7% vs. 60.5%, $P=0.004$). The mean follow-up period was 28.0 ± 10.2 months, which was not statistically different between the 2 groups.

2. CDCI and allergic disease outcomes

Between ages 2 and 5 years, 12.3% (8 of 65) of the infants had parent-reported asthma, whereas 9.2% (6 of 65) of the infants had AR. The prevalence of AD was 9.2% (6 of 65) and the prevalence of FA was 4.6% (3 of 65). More infants with CDCI developed at least one allergic disease between ages 2 and 5 years compared to infants without CDCI ($P=0.007$) (Table 2). Food allergies were more prevalent in the *C. difficile*-positive group ($P=0.03$). Two children were allergic to eggs and 1 was allergic to soy. CDCI may be associated with a higher risk of development of at least one allergic disease (aOR, 5.60; 95% CI, 1.52–20.74; Table 2). However, the increased risks of asthma, AR, and AD were not statistically significant.

Discussion

This study demonstrated that the presence of CDCI during infancy was associated with a higher risk of development of at

least one allergic disease during childhood. An association between the presence of *C. difficile* and the development of allergic diseases was not found when allergic diseases were analyzed individually with the exception of FA. Antibiotic exposure was more common in the *C. difficile*-negative group ($P=0.004$) (Table 1). These findings may be explained by the results of previous studies showing that the incidence of community-acquired CDCI

Table 1. Baseline characteristics of the study population

Characteristic	<i>C. difficile</i> -positive (n=22)	<i>C. difficile</i> -negative (n=43)	P value
Male sex	14 (63.6)	19 (44.2)	0.19
Mode of delivery			0.29
Vaginal delivery	15 (68.2)	23 (53.5)	
Cesarean section	7 (31.8)	20 (46.5)	
Gestational age (wk)			1.00
<37	3 (13.6)	5 (11.6)	
37–42	19 (86.4)	38 (88.4)	
>42	0 (0)	0 (0)	
Birth weight (g)			1.00
<2,500	2 (9.1)	3 (7.0)	
2,500–4,000	20 (90.9)	39 (90.7)	
>4,000	0 (0)	1 (2.3)	
Maternal age at birth (yr)			0.94
<25	0 (0)	1 (2.3)	
25–30	4 (18.2)	5 (11.6)	
31–35	11 (50.0)	21 (48.8)	
>35	3 (13.6)	7 (16.3)	
Unknown	4 (18.2)	9 (20.9)	0.97
Birth order			
1	11 (50.0)	15 (34.9)	
2	7 (31.8)	25 (58.1)	0.75
>3	4 (18.1)	3 (7.0)	
Duration of breastfeeding (mo)			
Never	5 (22.7)	8 (18.6)	
≤6	8 (36.4)	16 (37.2)	
>6	7 (31.8)	15 (34.9)	0.43
Unknown	2 (9.1)	4 (9.3)	0.004
NICU admission	2 (9.1)	7 (16.3)	0.57
Antibiotic exposure	5 (22.7)	26 (60.5)	0.14
Mother with allergic diseases	2 (9.1)	6 (14.0)	0.21
Father with allergic diseases	5 (22.7)	4 (9.3)	0.33
Parents with allergic diseases	0 (0)	3 (7.0)	0.55
Age at collection of fecal sample (mo)	6.0 ± 2.8	5.3 ± 2.9	0.24
Eosinophil blood count at enroll (cells/ μ L)	162.9 ± 36.3	192.7 ± 30.2	
Follow-up period (mo)	28.1 ± 8.6	27.9 ± 11.0	

Values are presented as number (%) or mean \pm standard deviation. P values were obtained using the chi-square test or Fisher exact test. *C. difficile*, *Clostridium difficile*.

in infants without antibiotic exposure reached 78% unlike in adults¹⁶. Moreover, the results suggest that the environmental sources like food, water, and animals, as well as host factors, may play an important role in community-acquired CDCl, and different strain types and genetic diversity of *C. difficile* can affect the diverse sources of CDCl¹⁸.

C. difficile in the intestinal microbiota, regardless of the strain, is significantly associated with modification of the composition of the microbial ecosystem¹⁴. It is likely that beneficial bacteria are replaced by overgrowth of pathogenic bacteria, thereby reducing the diversity of intestinal flora¹⁹. These alterations, such as delayed colonization with beneficial bacteria, might interfere with the development of immunologic tolerance. The absence of a proper immunosuppressive mechanism by regulatory T cells can result in an imbalance between T_H1 and T_H2 cells and, in turn, cause T_H1-mediated and T_H2-mediated inflammatory disease⁵.

Commensal bacteria that normally populate the gastrointestinal tract influence allergic responses to food. In a recent study of the association between altered commensal microbiota and food allergen sensitization, the intestinal microbiota was found to regulate innate lymphoid cell function and intestinal epithelial permeability in mice, and sensitization to food is regulated by these innate mechanisms²⁰. Bisgaard et al.¹⁹ found that reduced diversity in the human microbiome is a possible risk factor for life style-related disorders such as atopic disease, possibly through a modifying influence on immune maturation during infancy. Reduced diversity of the intestinal microbiota was causally related to FA in previous studies of the infantile microbiome and allergic disease^{21,22}. These findings are similar to those of our study regarding differences in FA between the *C. difficile*-positive (13.6%) and *C. difficile*-negative groups (0%) ($P=0.03$) (Table 2). We hypothesized that the presence of *C. difficile* in the intestinal microbiota might possibly reflect the reduced diversity of the intestinal microbiota, which is associated with an increased risk of allergic sensitization. This is in agreement with previous studies^{23,24}. However, the mechanisms that change the composition of the intestinal microbiota, which regulates allergic responses to

food, are unclear. Therefore, additional research of the association between the actual composition of the gastrointestinal microbiota and the development of FA should focus on the presence of *C. difficile*.

The association between *C. difficile* colonization and/or infection and AR has not been reported previously. In the present study, CDCl were not associated with the development of AR. However, several studies have reported the role of probiotics in the treatment of AR^{25,26}. Probiotic treatment for AR is associated with lower symptom scores and medication use²⁵, suggesting that there is a relationship between gastrointestinal microbiota and AR.

In our study, CDCl were not associated with the development of AD or asthma. This is partly in agreement with the results of a previous study that intestinal bacterial diversity unrelated with the development of asthma or AD, which was explained by the different genetics²⁷. However, another study reported that colonization by *C. difficile* at the age of one month was associated with asthma and AD throughout the first 6 to 7 years of life⁵. Therefore, the influence of the intestinal microbiota on the development of AD and asthma remains controversial, and a large-scale prospective study may be necessary for further investigation.

This is one of the few studies that have shown that CDCl at ages 1 to 12 months after settlement of normal flora in the gastrointestinal tract could influence the development of allergic diseases during early childhood, which might partially explain the effect of the gastrointestinal microbiota on allergic diseases. Because the understanding of the profound influence of commensal microbes on maturation of the immune system has grown, strategies that reduce changes in the composition of the intestinal microbiota may have broad benefits. One such strategy would be cautious use of antibiotics. Several lines of evidence confirm that antibiotic administration can result in gut microbiota dysbiosis, i.e., disturbance in composition and function²⁸. In particular, antibiotic use during infancy strongly perturbs intestinal bacterial populations and has often been cited as a contributing factor to the increasing prevalence of allergic diseases²⁰.

Table 2. Associations between the presence of *Clostridium difficile* colonization and/or infection in infancy and allergic manifestation at the age of 2–5 years

Variable	<i>C. difficile</i> -positive (n=22)	<i>C. difficile</i> -negative (n=43)	P value	Crude OR (95% CI)	Adjusted OR* (95% CI)
Asthma	5 (22.7)	3 (7.0)	0.10	3.92 (0.84–18.29)	3.03 (0.48–19.14)
Allergic rhinitis	4 (18.2)	2 (4.7)	0.16	4.55 (0.76–27.16)	4.42 (0.63–31.24)
Atopic dermatitis	4 (18.2)	2 (4.7)	0.16	4.55 (0.76–27.16)	5.92 (0.64–55.28)
Food allergy	3 (13.6)	0 (0)	0.03	NS	NS
At least 1 allergic disease [†]	11 (50.0)	7 (16.3)	0.007	5.14 (1.61–6.46)	5.60 (1.52–20.74)

Values are presented as number (%) unless otherwise indicated.

Logistic regression models were used to estimate adjusted odds ratios (aORs).

CI, confidence interval; NS, Not significant.

*Adjusted for sex, age, gestational age, birth weight, breast feeding, and parents with allergic diseases. [†]Allergic diseases included asthma, allergic rhinitis, atopic dermatitis, and food allergies.

The present study has several limitations. First, this study used stool samples for gut microbiota analysis, which might not reflect the composition of the intestinal tract. Nevertheless, it can be assumed that the dominant microbiota in the intestinal tract should be detectable in the feces by a culture test. Second, because infants enrolled in this study were limited to patients who were admitted to the hospital with specific symptoms, they could not represent the community. Third, the data regarding allergic diseases in children were collected via parental report questionnaires without physical examinations performed by doctors. Therefore, the prevalence rates of allergic diseases might have been overestimated. In addition, the parents answered questions based on their memory, which make responses highly subjective. These responses might have been influenced by recall bias. Fourth, stool tests were performed only once. Therefore, we could not rule out the possibility of CDCI after this study in the *C. difficile*-negative group. Finally, we did not determine the allergic disease factors, such as vitamin D levels, respiratory virus, and air pollution, in this study.

In conclusion, CDCI might be associated with a higher risk of developing at least one allergic disease. These results suggest the probability of a causal relationship between changes in the intestinal microbiota composition and the development of allergic diseases during early childhood. To confirm the effect of CDCI on the development of allergic diseases, further prospective research involving measurements of serum IgE levels and larger cohorts are required. Furthermore, because the prevalence of allergic diseases usually changes according to age, longer follow-up studies are needed. Finally, more detailed studies are needed to determine how the diverse microbiota could influence immune responses in infants.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". *Thorax* 2000;55 Suppl 1:S2-10.
2. Kummeling I, Stelma FF, Dagnelie PC, Snijders BE, Penders J, Huber M, et al. Early life exposure to antibiotics and the subsequent development of eczema, wheeze, and allergic sensitization in the first 2 years of life: the KOALA Birth Cohort Study. *Pediatrics* 2007;119:e225-31.
3. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. *Gut* 2007;56:661-7.
4. Vebø HC, Sekelja M, Nestestog R, Storrø O, Johnsen R, Øien T, et al. Temporal development of the infant gut microbiota in immunoglobulin E-sensitized and nonsensitized children determined by the GA-map infant array. *Clin Vaccine Immunol* 2011;18:1326-35.
5. van Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman GH, Kerkhof M, et al. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. *J Allergy Clin Immunol* 2011;128:948-55.e1-3.
6. Strachan DP. Hay fever, hygiene, and household size. *BMJ* 1989;299:1259-60.
7. Noverr MC, Huffnagle GB. The 'microflora hypothesis' of allergic diseases. *Clin Exp Allergy* 2005;35:1511-20.
8. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. *Science* 2012;336:489-93.
9. Chu KH, Chiang BL. Regulatory T cells induced by mucosal B cells alleviate allergic airway hypersensitivity. *Am J Respir Cell Mol Biol* 2012;46:651-9.
10. Liao SL, Yeh KW, Lai SH, Lee WI, Huang JL. Maturation of Toll-like receptor 1-4 responsiveness during early life. *Early Hum Dev* 2013;89:473-8.
11. Bryant K, McDonald LC. Clostridium difficile infections in children. *Pediatr Infect Dis J* 2009;28:145-6.
12. Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. *Int J Antimicrob Agents* 2009;33 Suppl 1:S24-8.
13. Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. *Infect Control Hosp Epidemiol* 2011;32:220-8.
14. Rousseau C, Levenez F, Fouqueray C, Doré J, Collignon A, Lepage P. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. *J Clin Microbiol* 2011;49:858-65.
15. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 2011;331:337-41.
16. Cho HJ, Ryoo E, Sun YH, Cho KH, Son DW, Tchah H. Epidemiology and Clinical Characteristics of Clostridium difficile-associated Disease in Children: Comparison between Community- and Hospital-acquired Infections. *Korean J Pediatr Gastroenterol Nutr* 2010;13:146-53.
17. Choi SW, Ju YS, Kim DS, Kim JY, Kwon HJ, Kang DH, et al. Reliability and Validity of the Korean Version of ISAAC Questionnaire. *Korean J Prev Med* 1998;31:361-71.
18. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. *Infect Drug Resist* 2014;7:63-72.
19. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Müller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. *J Allergy Clin Immunol* 2011;128:646-52.e1-5.
20. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK, et al. Commensal bacteria protect against food allergen sensitization. *Proc Natl Acad Sci U S A* 2014;111:13145-50.
21. Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, et al. Reduced diversity in the early fecal microbiota of infants with atopic eczema. *J Allergy Clin Immunol* 2008;121:129-34.
22. Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. *J Allergy Clin Immunol* 2012;129:434-40, 440.e1-2.
23. Vincent C, Stephens DA, Loo VG, Edens TJ, Behr MA, Dewar K, et

- al. Reductions in intestinal Clostridiales precede the development of nosocomial *Clostridium difficile* infection. *Microbiome* 2013; 1:18.
24. Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and *Clostridium difficile* colonization or infection. *Microbiome* 2016;4:12.
25. Das RR, Singh M, Shafiq N. Probiotics in treatment of allergic rhinitis. *World Allergy Organ J* 2010;3:239-44.
26. Vliagoftis H, Kouranos VD, Betsi GI, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. *Ann Allergy Asthma Immunol* 2008; 101:570-9.
27. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med* 2010;363:1211-21.
28. Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. *Front Microbiol* 2016;6: 1543.